Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know
oleh: Alexander Meisel
| Format: | Article |
|---|---|
| Diterbitkan: | THE HEALTHBOOK COMPANY LTD. 2020-03-01 |
Deskripsi
The recent advances in EGFR M+ NSCLC and the availability of different treatment options, including treatment novelities such as osimertinib and afatinib, are summarized in this review.